What You Need to Know About Eye Changes After Starting Hybrid Closed-Loop Insulin Pumps

Hybrid closed-loop (HCL) systems—automated insulin pumps that adjust delivery throughout the day—represent a major advance in Type 1 diabetes management. They can quickly improve blood sugar control in ways that were previously difficult to achieve. But a curious and counterintuitive phenomenon has emerged: the faster blood sugar improves, the more likely a person's eyes may show temporary changes.

This phenomenon, called early worsening of diabetic retinopathy (EWDR), was first noticed during the intensive insulin therapy era decades ago. Now researchers wanted to know: does starting an HCL system carry a meaningful risk of this eye change?

A systematic review published in July 2026 examined eight studies involving 1,487 people with Type 1 diabetes, 860 of whom used hybrid closed-loop systems. The goal was to see how often early worsening of retinopathy occurred after HCL initiation.

The results were mixed. When researchers looked at studies that checked eye health within 12 months of starting an HCL system, the rate of early worsening ranged from 8.9% to 26.5%. This wide range is important: it suggests the rates depend heavily on how and when doctors measured the eyes, and how they defined 'early worsening.'

The review found significant variation in how studies were conducted, which makes it hard to say what the 'true' risk really is. Different studies used different definitions of early worsening, checked eyes at different time points after starting HCL, followed people for different lengths of time, and compared HCL to different control treatments (or to no control at all).

Because of this heterogeneity, the reviewers did not combine the studies into a single estimate. Instead, they presented what each study found individually—a more honest approach when the studies differ substantially.

All eight studies included were observational, meaning researchers watched what happened rather than randomly assigning people to use HCL or a comparison treatment. Six of the eight were also retrospective, relying on medical records from the past. These study designs are useful for raising questions but cannot prove cause and effect.

The review does not suggest that HCL systems are unsafe or should be avoided. Rather, it highlights an area where more rigorous research is needed. Future studies should use clear, consistent definitions of early worsening; establish consistent timing for eye checks; and include longer follow-up to learn whether temporary changes resolve on their own and how long they typically last.

If you or a family member is considering starting a hybrid closed-loop system, this review does not change the fact that HCL systems can improve blood sugar control significantly. However, it underscores the importance of maintaining regular eye exams with an eye care specialist before and after starting any new insulin therapy.

Discuss any concerns about eye health with your diabetes care team and eye doctor. They can help monitor for changes and determine whether any temporary worsening is occurring and how best to manage it alongside the benefits of improved glycemic control.

Source: Diabetes, obesity & metabolism. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.